Future studies should shed light on whether targeting PC-OxPL is sufficient to consider improvements on clinical endpoints for SOD1-associated ALS, also by comparison to current approved strategies, such as Tofersen® (Hamad et al., 2025). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.